- Home
- ASC vs KROS Comparison
ASC vs KROS Comparison
Compare ASC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- KROS
- Stock Information
- Founded
- ASC 2010
- KROS 2015
- Country
- ASC Bermuda
- KROS United States
- Employees
- ASC N/A
- KROS N/A
- Industry
- ASC Marine Transportation
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- KROS Health Care
- Exchange
- ASC Nasdaq
- KROS Nasdaq
- Market Cap
- ASC 511.3M
- KROS 589.8M
- IPO Year
- ASC 2013
- KROS 2020
- Fundamental
- Price
- ASC $12.23
- KROS $10.86
- Analyst Decision
- ASC Buy
- KROS Buy
- Analyst Count
- ASC 3
- KROS 11
- Target Price
- ASC $20.00
- KROS $45.33
- AVG Volume (30 Days)
- ASC 759.6K
- KROS 2.0M
- Earning Date
- ASC 02-13-2025
- KROS 02-26-2025
- Dividend Yield
- ASC 8.82%
- KROS N/A
- EPS Growth
- ASC 6.23
- KROS N/A
- EPS
- ASC 3.55
- KROS N/A
- Revenue
- ASC $422,624,000.00
- KROS $651,000.00
- Revenue This Year
- ASC N/A
- KROS $303.39
- Revenue Next Year
- ASC N/A
- KROS N/A
- P/E Ratio
- ASC $3.45
- KROS N/A
- Revenue Growth
- ASC N/A
- KROS 8037.50
- 52 Week Low
- ASC $10.86
- KROS $9.78
- 52 Week High
- ASC $23.44
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- ASC 47.77
- KROS 20.25
- Support Level
- ASC $12.83
- KROS $9.78
- Resistance Level
- ASC $13.85
- KROS $16.49
- Average True Range (ATR)
- ASC 0.47
- KROS 0.92
- MACD
- ASC 0.05
- KROS 0.97
- Stochastic Oscillator
- ASC 24.65
- KROS 14.52
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.